Profil Keamanan Obat Bedaquiline terhadap Jantung pada Pengobatan Tuberkulosis Resisten Obat

I. Gusti Agung Ayu Putu Sri Darmayani, Purwanty Astuti Ascobat

Research output: Contribution to journalArticlepeer-review

Abstract

Bedaquiline is a new antibiotic particularly developed for the treatment of drug-resistant tuberculosis. Based on the results of studies during drug development, the safety aspect of bedaquiline to the heart was a major concern, since it caused prolongation of QT interval. However, this safety concerns were obtained by observing only small number of patients with incomplete cardiac safety monitoring data. Additional safety data of the heart needs to be systematically collected after the drug is widely used as a programmatic drug. Services and patient safety will be enhanced by implementing active drug safety monitoring (aDSM) from WHO.
Original languageEnglish
JournalIndonesian Journal of CHEST : Critical and Emergency Medicine
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Profil Keamanan Obat Bedaquiline terhadap Jantung pada Pengobatan Tuberkulosis Resisten Obat'. Together they form a unique fingerprint.

Cite this